Optic Neuropathy - Pipeline Review, H1 2020
Optic Neuropathy - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy - Overview
Optic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy - Companies Involved in Therapeutics Development
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Optic Neuropathy - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELN-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fab-3H4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dominant Optic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
May 14, 2019: Regenera announces publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology
Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting
Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of RPh201
Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’
Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Optic Neuropathy - Overview
Optic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy - Companies Involved in Therapeutics Development
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Optic Neuropathy - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELN-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fab-3H4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dominant Optic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
May 14, 2019: Regenera announces publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology
Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting
Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of RPh201
Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’
Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuropathy - Pipeline by Allergan Plc, H1 2020
Optic Neuropathy - Pipeline by Antoxis Ltd, H1 2020
Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H1 2020
Optic Neuropathy - Pipeline by PharmatrophiX Inc, H1 2020
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2020
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Dormant Projects, H1 2020
Optic Neuropathy - Discontinued Products, H1 2020
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuropathy - Pipeline by Allergan Plc, H1 2020
Optic Neuropathy - Pipeline by Antoxis Ltd, H1 2020
Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H1 2020
Optic Neuropathy - Pipeline by PharmatrophiX Inc, H1 2020
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2020
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Dormant Projects, H1 2020
Optic Neuropathy - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
